2024 Overview 

Market Growth and Drivers 

For biologics CDMOs, 2024 was shaped by intensifying demand for specialized manufacturing infrastructure. The global biologics and ATs CDMO market reached $20.7 billion, driven by continued innovation in monoclonal antibodies, increased outsourcing by emerging biotech, and the need for flexible capacity. Investments in viral vector production, cell processing, and cold chain logistics remain central to sponsors’ outsourcing strategies. 

Operational and Regulatory Complexity 

Market dynamics in 2024 were shaped by persistent capacity bottlenecks, increasing modality complexity, and heightened regulatory expectations. The commercialization of next-generation therapies, particularly cell and gene therapy technologies, demanded greater operational agility from CDMOs, with sponsors favoring end-to-end service providers equipped with integrated compliance and quality systems. 

Consolidation and Strategic Priorities

Market consolidation continued at the top, with the eight largest CDMOs capturing over 50% of global revenue. Demand from biopharma sponsors continued to concentrate on platforms that combine global scale with modality-specific expertise, particularly those capable of supporting complex programs across the full development-to-commercialization continuum. Fill-finish, commercial manufacturing, and analytical development remained the most frequently acquired capabilities, while regional expansions emphasized geographic risk diversification.  

Investment and M&A Activity 

Investment activity remained cautious. A total of 17 mergers and acquisitions (M&A) transactions were recorded in 2024, down from 27 in 2023. Strategic acquirers remained active, targeting fill-finish, sterile injectables, and platform-based CDMOs. Private equity (PE) activity was limited, shaped by selective asset targeting. Only four new PE-backed platforms were established, with investors favoring resilient, modality-aligned capabilities over broad buy-and-build strategies. 

Structural and Regulatory Shifts 

In 2024, structural shifts in the CDMO landscape included the growing importance of early-stage integration and a preference for modality-diverse infrastructure. Concurrently, regulatory developments, including the updated European Medicines Agency (EMA) and Food and Drug Administration (FDA) guidelines for advanced therapy medicinal products (ATMPs), reinforced the need for stringent good manufacturing practice (GMP) compliance and enhanced data transparency across development and manufacturing. 

2025 Outlook 

Continued Market Momentum 

The biologics CDMOs market is expected to maintain solid momentum through 2025, with growth led by high-demand segments such as GLP-1s, bispecific antibodies, and viral vector platforms. While structurally attractive, the sector is increasingly shaped by regulatory complexity, evolving sponsor expectations, and recalibration of global manufacturing footprints. 

Sponsor Demand and Outsourcing Trends 

Demand remains strong across core therapeutic areas, particularly in immunology, oncology, and metabolic disease, driven by a maturing pipeline of complex biologics and ATs. Outsourcing continues to be a strategic imperative, though sponsors are becoming increasingly selective, favoring CDMOs with robust compliance systems, digital quality infrastructure, and the capacity to scale across multiple modalities. 

Global Manufacturing Rebalancing 

Global manufacturing strategies are undergoing rebalancing. In early 2025, proposed US tariffs and heightened scrutiny of Chinese pharmaceutical supply chains prompted many sponsors to reassess geographic exposure. While legacy relationships remain largely intact, new program allocations are increasingly directed toward North America, Western Europe, and Asia-Pacific hubs with proven GMP compliance and regulatory credibility. CDMOs with dual-site capabilities and regional agility are well-positioned to benefit from this shift. 

ATs Manufacturing Under Focus 

ATs manufacturing remains under regulatory and commercial focus. Regulators in the US and EU are converging on tighter expectations for traceability, chain-of-identity, and real-time release testing, especially for personalized, autologous, and cell-based products. This is elevating the role of CDMOs with digital quality systems, closed-system operations, and platform-level capabilities. Modalities such as viral vectors, lipid nanoparticles, and small-scale aseptic fill-finish remain capacity-constrained, reinforcing the strategic value of flexible, specialized infrastructure. 

Investment Outlook

On the investment side, Q1 2025 was marked by subdued deal activity. However, investor sentiment is gradually improving as capital markets stabilize. PE interest is expected to return with increased selectivity, targeting CDMOs with differentiated capabilities, visible commercial pipelines, and latent capacity. Strategic acquirers are also expected to re-engage, particularly in bolt-on acquisitions that strengthen modality-specific capabilities or expand end-to-end service offerings. 

Keys to Future Growth 

As the year progresses, market dynamics are expected to favor CDMOs that combine technical specialization with operational agility and can navigate regulatory complexity, adapt to geographic realignment, and consistently deliver on commercial execution. Growth in 2025 will be shaped not only by demand fundamentals, but also by the ability of CDMOs to function as reliable, compliant, and innovation-ready partners in a dynamic global environment.

Looking Ahead

The global biologics CDMO market is projected to reach $31.9 billion by 2029, with gene and cell therapies expected to account for over 20% of total value. This shift reflects a broader industry evolution from high-volume monoclonal antibody production to precision-based, modality-diverse portfolios, driving demand for highly specialized and adaptive CDMO capabilities. 

Go Beyond Market Insights

If you are interested in working with our experts in this market, learn more about our biologics CDMO consulting support.